KalVista Pharmaceuticals’ (KALV) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV) in a report released on Tuesday morning, Benzinga reports. They currently have a $35.00 price objective on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reduced their price target on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a buy rating for the company in a research report on Friday, May 3rd.

KalVista Pharmaceuticals Trading Down 3.8 %

Shares of NASDAQ:KALV opened at $11.37 on Tuesday. The company has a market capitalization of $479.70 million, a PE ratio of -3.61 and a beta of 0.90. KalVista Pharmaceuticals has a twelve month low of $7.21 and a twelve month high of $16.88. The firm has a 50 day simple moving average of $11.73 and a 200-day simple moving average of $12.25.

Insider Activity at KalVista Pharmaceuticals

In related news, insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $95,114.88. Following the completion of the sale, the insider now owns 72,858 shares in the company, valued at approximately $856,810.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $11.53, for a total transaction of $86,071.45. Following the completion of the transaction, the chief executive officer now owns 224,547 shares in the company, valued at approximately $2,589,026.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $95,114.88. Following the transaction, the insider now owns 72,858 shares of the company’s stock, valued at approximately $856,810.08. The disclosure for this sale can be found here. Insiders sold a total of 37,512 shares of company stock worth $439,424 in the last 90 days. 12.30% of the stock is owned by insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of large investors have recently bought and sold shares of KALV. Capital World Investors purchased a new position in KalVista Pharmaceuticals during the 1st quarter worth $17,370,000. StemPoint Capital LP grew its stake in shares of KalVista Pharmaceuticals by 174.4% during the 1st quarter. StemPoint Capital LP now owns 1,161,060 shares of the specialty pharmaceutical company’s stock worth $13,770,000 after purchasing an additional 737,886 shares during the period. Frazier Life Sciences Management L.P. grew its stake in shares of KalVista Pharmaceuticals by 11.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after purchasing an additional 383,435 shares during the period. Vanguard Group Inc. grew its stake in shares of KalVista Pharmaceuticals by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after purchasing an additional 151,808 shares during the period. Finally, Affinity Asset Advisors LLC grew its stake in shares of KalVista Pharmaceuticals by 56.1% during the 3rd quarter. Affinity Asset Advisors LLC now owns 278,292 shares of the specialty pharmaceutical company’s stock worth $2,680,000 after purchasing an additional 100,000 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.